NO20056027L - Surrogat terapeutisk endepunkt for anti-CTLA-4 basert immunoterapi av sykdom - Google Patents

Surrogat terapeutisk endepunkt for anti-CTLA-4 basert immunoterapi av sykdom

Info

Publication number
NO20056027L
NO20056027L NO20056027A NO20056027A NO20056027L NO 20056027 L NO20056027 L NO 20056027L NO 20056027 A NO20056027 A NO 20056027A NO 20056027 A NO20056027 A NO 20056027A NO 20056027 L NO20056027 L NO 20056027L
Authority
NO
Norway
Prior art keywords
ctla
based disease
therapeutic endpoint
surrogate therapeutic
disease immunotherapy
Prior art date
Application number
NO20056027A
Other languages
English (en)
Other versions
NO344368B1 (no
Inventor
Israel Lowy
Geoffrey M Nichol
Original Assignee
Medarex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Llc filed Critical Medarex Llc
Publication of NO20056027L publication Critical patent/NO20056027L/no
Publication of NO344368B1 publication Critical patent/NO344368B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Sammendrag Det beskrives en fremgangsmåte for behandling av humansekvens antistoffer mot human CTLA-4. Særlig beskrives det metoder for behandling av kanser.
NO20056027A 2003-05-30 2005-12-19 Anti-CTLA-4 antistoff til bruk i behandling av kreft i en pasient. NO344368B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47506703P 2003-05-30 2003-05-30
PCT/US2004/016995 WO2005003298A2 (en) 2003-05-30 2004-05-28 Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease

Publications (2)

Publication Number Publication Date
NO20056027L true NO20056027L (no) 2006-02-20
NO344368B1 NO344368B1 (no) 2019-11-18

Family

ID=33563738

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056027A NO344368B1 (no) 2003-05-30 2005-12-19 Anti-CTLA-4 antistoff til bruk i behandling av kreft i en pasient.

Country Status (19)

Country Link
US (2) US7465446B2 (no)
EP (1) EP1639010B1 (no)
JP (1) JP2007502330A (no)
CN (1) CN1816567A (no)
AU (1) AU2004253865B2 (no)
CA (1) CA2527373A1 (no)
CY (1) CY1123535T1 (no)
DK (1) DK1639010T3 (no)
ES (1) ES2813928T3 (no)
HU (1) HUE051533T2 (no)
IL (1) IL172028A (no)
MX (1) MXPA05012832A (no)
NO (1) NO344368B1 (no)
NZ (1) NZ543768A (no)
PL (1) PL1639010T3 (no)
PT (1) PT1639010T (no)
SI (1) SI1639010T1 (no)
WO (1) WO2005003298A2 (no)
ZA (1) ZA200510125B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ536420A (en) * 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
CA2566745A1 (en) 2004-05-20 2005-12-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
GB0426644D0 (en) * 2004-12-03 2005-01-05 Univ Aberdeen T-cell modulation
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7611702B2 (en) * 2005-11-08 2009-11-03 Medarex, Inc. TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
WO2007056539A2 (en) * 2005-11-08 2007-05-18 Medarex, Inc. Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
NZ568016A (en) * 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010042433A1 (en) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
US8435516B2 (en) * 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
US8778618B2 (en) 2010-04-16 2014-07-15 The Johns Hopkins University Compositions and methods for characterizing a myopathy
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
JP6074435B2 (ja) 2011-10-26 2017-02-01 ナショナル キャンサー センター 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物
WO2013169971A1 (en) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
SG11201907867TA (en) 2017-02-28 2019-09-27 Bristol Myers Squibb Co Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
IL270743B2 (en) 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
CA3102334A1 (en) 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
IL287801A (en) * 2019-05-07 2022-07-01 Immunicom Inc Increasing responses to checkpoint inhibitors by extracorporeal apheresis
WO2022229644A1 (en) 2021-04-28 2022-11-03 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
WO2024212152A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anti-ctla4 antibodies and methods of making and using the same
WO2025052098A1 (en) 2023-09-08 2025-03-13 Mina Therapeutics Limited Tmem173 sarna compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014424A2 (en) * 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014424A2 (en) * 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN ELSAS, ANDREA ET AL., "Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation, Journal of Experimental Medicine, vol. 190, nr. 3, 1999, side 355-366, Dated: 01.01.0001 *

Also Published As

Publication number Publication date
EP1639010B1 (en) 2020-06-10
HUE051533T2 (hu) 2021-03-01
AU2004253865B2 (en) 2011-06-23
JP2007502330A (ja) 2007-02-08
SI1639010T1 (sl) 2020-10-30
WO2005003298A2 (en) 2005-01-13
US20090074752A1 (en) 2009-03-19
US7465446B2 (en) 2008-12-16
EP1639010A2 (en) 2006-03-29
CY1123535T1 (el) 2022-03-24
AU2004253865A1 (en) 2005-01-13
WO2005003298A3 (en) 2005-06-23
EP1639010A4 (en) 2006-08-09
NO344368B1 (no) 2019-11-18
MXPA05012832A (es) 2006-02-13
CA2527373A1 (en) 2005-01-13
US20040241169A1 (en) 2004-12-02
ES2813928T3 (es) 2021-03-25
IL172028A (en) 2012-01-31
US7744875B2 (en) 2010-06-29
PT1639010T (pt) 2020-09-04
CN1816567A (zh) 2006-08-09
DK1639010T3 (da) 2020-09-07
NZ543768A (en) 2009-07-31
ZA200510125B (en) 2006-12-27
PL1639010T3 (pl) 2020-11-30

Similar Documents

Publication Publication Date Title
CY1123535T1 (el) Υποκαταστατο θεραπευτικο τελικο σημειο για βασιζομενη σε anti-ctla-4 ανοσοθεραπεια ασθενειας
ATE552849T1 (de) Behandlungsverfahren unter verwendung von ctla-4 antikörpern
DE60329823D1 (de) Antikörper mit t-zell-rezeptor-artiger spezifität, aber höherer affinität und seine verwendung zum nachweis und zur behandlung von krebs, virusinfektionen und autoimmunkrankheiten
MA29595B1 (fr) Anticorps anti-cd40 humanises et procedes d'utilisation
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
NO20060843L (no) RG1-antistoffer og anvendelser derav
MX2010006181A (es) Anticuerpos monoclonales il-21 anti-humanos.
NO20080012L (no) Fremgangsmater for behandling av hjernetumorer med antistoffer
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
WO2011127412A3 (en) Soluble human st-2 antibodies and assays
NO20045645L (no) Noytraliserende humant anti-IGFR-antistoff
MXPA04011550A (es) Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico.
DK1766093T3 (da) Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
MXPA06003788A (es) Anticuerpos completamente humanos contra 4-1bb humano (cd137).
NO20062087L (no) Bispesifikt antistoff som substituerer for funksjonelle proteiner
CY2022028I1 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
NO20073414L (no) Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4)
ATE528319T1 (de) Krebsbehandlung mit anti-il-1-antikörpern
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
TW200517124A (en) Fully human antibodies against human 4-1BB
TW200635946A (en) Binding proteins specific for human matriptase
DK1713830T3 (da) Anti-epcam-immunglobuliner

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MEDAREX, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: E.R. SQUIBB & SONS, US